Atossa Genetics, Inc. 2012 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2012. The filing identifies the registrant as Atossa Genetics, Inc.; the request metadata refers to Atossa Therapeutics, Inc. The company was a development-stage healthcare company focused on breast-cancer prevention diagnostics and intraductal treatment research.
Business Context
- Commercial products were the ForeCYTE Breast Health Test, which uses the MASCT device and laboratory analysis of nipple aspirate fluid, and the ArgusCYTE blood test for circulating tumor cells.
- FullCYTE and NextCYTE were in development, with intended 2013 launches. The company also pursued preclinical intraductal treatment research for precancerous lesions and DCIS.
- By December 31, 2012, 37 doctors and clinics had enrolled, 1,664 ForeCYTE samples representing 832 patients had been processed, and 41 ArgusCYTE samples had been processed.
- In September 2012, the company acquired substantially all Acueity Healthcare assets, including patents, patent applications, six 510(k) authorizations and $400,000 of cash, in exchange for 862,500 shares and warrants for 325,000 shares.
Financial Results and Key Metrics
| Metric | 2012 | 2011 |
|---|---|---|
| Total revenue | $481,842 | $1,500 |
| Diagnostic testing service revenue | $475,402 | $0 |
| Product revenue | $6,440 | $1,500 |
| Gross profit | $416,213 | $(95,690) |
| Operating expenses | $5,485,243 | $3,333,500 |
| Operating loss | $(5,069,030) | $(3,429,190) |
| Net loss | $(5,079,851) | $(3,442,269) |
| Basic and diluted loss per share | $(0.41) | $(0.38) |
| Cash and cash equivalents at year-end | $1,725,197 | $1,910,821 |
| Net cash used in operating activities | $(3,899,964) | $(3,492,364) |
| Net cash used in investing activities | $(134,582) | $(136,931) |
| Net cash provided by financing activities | $3,848,922 | $5,529,863 |
- Revenue increased substantially but remained immaterial relative to operating costs. The reported gross margin was approximately 86%, primarily because diagnostic service revenue carried relatively low recorded direct costs; product economics were unfavorable because MASCT systems were sold below manufacturing cost.
- Research and development expense was $1,976,638 in 2012. General and administrative expense was $5,018,422, including $1,072,992 of legal expense and $232,291 of accounting expense. Selling expense was $466,821.
- The company recorded a $29,884 inventory write-down to lower of cost or market. ForeCYTE and ArgusCYTE collection kits distributed at no charge generated $55,282 of selling expense.
- Year-end total assets were $6,826,133, including $4,640,224 of net intangible assets, largely patents acquired from Acueity. Current liabilities were $1,650,598, including $1,582,381 of accrued expenses.
- The $1 million bank line of credit was repaid in October 2012; no line-of-credit balance remained at year-end. No material long-term debt was reported.
Material Changes Versus 2011
- Revenue increased from $1,500 to $481,842, driven almost entirely by ForeCYTE and ArgusCYTE testing services.
- Gross profit improved from a $95,690 loss to $416,213, but the net loss increased 48% to $5,079,851 as operating expenses rose 65%.
- Cash declined by $185,624 despite approximately $3.85 million of financing cash inflows, reflecting $3.90 million of operating cash burn and repayment of the $1 million bank line.
- Intangible assets increased from $40,841 to $4,640,224 following the Acueity acquisition. Stockholders’ equity increased to $5,175,535, supported by the November 2012 initial public offering and equity issued for the Acueity assets.
- The company became publicly traded on Nasdaq in November 2012 through an offering of 800,000 shares at $5.00 per share, generating approximately $3.454 million of net proceeds according to the financial statements.
Outlook, Risks and Unusual Items
- Management expected continued operating losses and estimated that $4 million to $10 million of additional capital would be needed to fund operations for at least the next 12 months. Year-end resources were expected to fund planned operations only through approximately the first four months of 2013.
- The independent auditor’s report and the financial statements included a going-concern uncertainty because the company had not established recurring revenue sufficient to cover operating costs and depended on additional financing.
- In January 2013, the company launched a national ForeCYTE sales effort through Clarity Women’s Health and its distributor network. The filing did not provide a quantitative revenue forecast.
- On February 21, 2013, the FDA issued a Warning Letter concerning the MASCT System, including alleged changes requiring an additional 510(k) submission, marketing matters and current Good Manufacturing Practice compliance. The company responded on March 13, 2013; no liability was recorded, but additional regulatory action, a new clearance requirement, a change back to the prior processing method or disruption of sales remained possible.
- On March 27, 2013, Aspire Capital committed to purchase up to $30 million of common stock over three years, subject to contractual and registration conditions. Aspire initially purchased 83,333 shares for $1 million. Future equity sales could dilute existing holders.
- Pending litigation by former President Robert Kelly and Victor Cononi involved contract termination and rescission-related claims. The company recorded no liability and stated that the amounts sought by Mr. Cononi were not specified; Mr. Kelly sought $450,000 in compensatory damages in the related arbitration claim.
- Key operating risks included limited commercialization history, uncertain physician adoption, incomplete reimbursement for the NAF collection procedure, dependence on third-party manufacturers and distributors, FDA and CLIA compliance, laboratory execution, competition and the need to obtain additional financing.
Important Facts for Investors to Verify
- Confirm the filing’s legal entity name and whether it is being associated with Atossa Therapeutics, Inc. for the intended analysis.
- Reconcile reported revenue, accounts receivable, reimbursement collections and the company’s policy of recognizing certain non-Medicare amounts only when cash is received.
- Assess cash runway, the $4 million to $10 million funding requirement and the practical availability of the Aspire equity facility after registration and market-volume limitations.
- Monitor resolution of the FDA Warning Letter and any additional 510(k), manufacturing, marketing or sales restrictions affecting the MASCT System.
- Evaluate whether ForeCYTE and ArgusCYTE achieve sustained reimbursement and commercial adoption, particularly because the NAF collection procedure was not broadly reimbursed.
- Review dilution from outstanding options, warrants, Acueity consideration, Aspire financing and other subsequent share issuances.
- Track the Kelly and Cononi claims, future lease obligations of approximately $508,967, and any other contingencies not accrued at December 31, 2012.